Measuring the Impact of Liquid Biopsy on Clinical Decision Making for NSCLC Patients

Measuring the Impact of Liquid Biopsy on Clinical Decision Making for NSCLC Patients

In this video, 2017 Penn Center for Precision Medicine Accelerator Fund recipient Erica Carpenter, MBA, PhD, describes her lab’s effort to validate the accelerated and broadened use of non invasive liquid biopsies to test for circulating tumor DNA in non-small cell lung cancer patients. Dr. Carpenter is a Research Assistant Professor of Medicine in the Division of Hematology-Oncology at Penn Medicine.

Related Links

Personalized Diagnostics for Hematologic and Solid Tumor Cancers

Dr. Carpenter’s Profile


Published

July 19, 2017

Created by

Penn Physician VideoLink